BRAF and non-small cell lung carcinoma: The American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) suggested the variants profiling of key driver genes in tissue such as EGFR, KRAS, BRAF, ALK, and ROS1 as a biomarker to predict targeted therapy for patients with advanced NSCLC [33,34].